 |
| Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia | Otsuka Pharmaceutical Co., Ltd. | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia | Otsuka Pharmaceutical Co., Ltd. | NA |
COMPLETED
(Sep 1, 2026)
| PHASE3 |
| A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD) | Otsuka Pharmaceutical Development & Commercialization, Inc. | NA |
RECRUITING
(Aug 1, 2026)
| PHASE3 |
| A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together | Otsuka Pharmaceutical Development & Commercialization, Inc. | NA |
RECRUITING
(Aug 1, 2026)
| PHASE1 |
| "SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia | Otsuka Pharmaceutical Development & Commercialization, Inc. | NA |
COMPLETED
(Jul 1, 2026)
| PHASE3 |
| A Study of Adjunctive Aripiprazole in Participants With Major Depressive Disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | NA |
COMPLETED
(Jul 1, 2026)
| PHASE3 |
| Study of Ascending Levels of Tolvaptan in Hyponatremia | Otsuka Pharmaceutical Development & Commercialization, Inc. | NA |
COMPLETED
(Jul 1, 2026)
| PHASE3 |
| Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD) | Otsuka Pharmaceutical Development & Commercialization, Inc. | NA |
COMPLETED
(Jul 1, 2026)
| PHASE3 |
| Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB | Otsuka Pharmaceutical Development & Commercialization, Inc. | NA |
COMPLETED
(Jul 1, 2026)
| PHASE2 |
| First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria | Otsuka Pharmaceutical Development & Commercialization, Inc. | NA |
COMPLETED
(Jul 1, 2026)
| PHASE1, PHASE2 |
| A Study in Adult Males With X-linked Congenital Nephrogenic Diabetes Insipidus to Test the Effects of NDI-5001 Given for Multiple Days and to Test How NDI-5001 is Tolerated and Taken up in the Body | Otsuka Pharmaceutical Development & Commercialization, Inc. | NA |
RECRUITING
(Jul 1, 2026)
| PHASE1 |
| A Study to Test the Effects of Itraconazole and Carbamazepine on OPC-167832 in Healthy Men and Women | Otsuka Pharmaceutical Development & Commercialization, Inc. | NA |
COMPLETED
(Jun 1, 2026)
| PHASE1 |
| Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents | Otsuka Pharmaceutical Development & Commercialization, Inc. | NA |
COMPLETED
(May 1, 2026)
| PHASE1 |
| Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | NA |
COMPLETED
(May 1, 2026)
| PHASE3 |
| A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis | Otsuka Pharmaceutical Development & Commercialization, Inc. | NA |
RECRUITING
(May 1, 2026)
| PHASE3 |
| Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD). | Otsuka Pharmaceutical Development & Commercialization, Inc. | NA |
COMPLETED
(Apr 1, 2026)
| PHASE3 |
| Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD) | Otsuka Pharmaceutical Development & Commercialization, Inc. | NA |
COMPLETED
(Apr 1, 2026)
| PHASE3 |
| IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients | Otsuka Pharmaceutical Development & Commercialization, Inc. | NA |
COMPLETED
(Apr 1, 2026)
| PHASE2 |
| A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users | Otsuka Pharmaceutical Development & Commercialization, Inc. | NA |
COMPLETED
(Apr 1, 2026)
| PHASE1 |
| A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers | Otsuka Pharmaceutical Development & Commercialization, Inc. | NA |
COMPLETED
(Apr 1, 2026)
| PHASE1 |
| A Phase 1 Study Comparing AVP-786 With AVP-923 | Otsuka Pharmaceutical Development & Commercialization, Inc. | NA |
COMPLETED
(Apr 1, 2026)
| PHASE1 |
| Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts | Otsuka Pharmaceutical Development & Commercialization, Inc. | NA |
COMPLETED
(Apr 1, 2026)
| PHASE1 |
| Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | NA |
COMPLETED
(Apr 1, 2026)
| PHASE1 |
| A Trial to Assess How Centanafadine Interacts With Stimulants in the Body | Otsuka Pharmaceutical Development & Commercialization, Inc. | NA |
COMPLETED
(Apr 1, 2026)
| PHASE1 |
| Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset Schizophrenia | Otsuka Pharmaceutical Europe Ltd |
H. Lundbeck A/S
|
UNKNOWN
(Apr, 2019)
| |
| Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features. | Otsuka Pharmaceutical Development & Commercialization, Inc. | NA |
TERMINATED
(Jan, 2016)
| PHASE3 |
| Aripiprazole for the Augmentation of Antidepressant Therapy | Taiwan Otsuka Pharm. Co., Ltd | NA |
COMPLETED
(May, 2014)
| PHASE4 |
| Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. |
Otsuka America Pharmaceutical
|
COMPLETED
(Feb, 2013)
| PHASE3 |
| Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. |
Otsuka America Pharmaceutical
|
COMPLETED
(Aug, 2008)
| PHASE4 |
| Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders | Otsuka Pharmaceutical Development & Commercialization, Inc. | NA |
COMPLETED
(Sep, 2007)
| PHASE2, PHASE3 |
